Pharma Focus Asia

Samsung Biologics Collaborates with Pfizer

Thursday, June 08, 2023

Samsung Biologics and Pfizer have recently announced a strategic partnership aimed at the long-term commercial manufacturing of Pfizer's diverse portfolio of products.

According to the terms of this agreement, Samsung Biologics will offer Pfizer additional capacity to meet the demands of a multi-product biosimilars portfolio. This portfolio will encompass therapeutic areas such as oncology, inflammation, and immunology. To support this manufacturing endeavour, Samsung Biologics will utilise its latest facility, known as Plant 4.

Together, this collaboration is poised to make a meaningful impact in the field of biopharmaceutical manufacturing and contribute to improving global healthcare outcomes.

This collaboration signifies a significant step forward in the mutual commitment to meet the growing demand for high-quality biopharmaceuticals on a global scale. 

By leveraging Samsung Biologics' state-of-the-art manufacturing capabilities and Pfizer's expertise in developing innovative therapies, this partnership aims to enhance production efficiency, ensure a stable supply chain, and ultimately deliver life-saving treatments to patients around the world.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024